Advertisement

Topics

Pharmacyclics Incorporated Company Profile

09:06 EDT 23rd September 2017 | BioPortfolio

Pharmacyclics, Inc. is a pharmaceutical company developing energy-potentiating drugs to improve radiation therapy andchemotherapy of cancer, and to enable or improve the photodynamic therapy of certain cancers, atherosclerotic cardiovascular disease and retinal diseases. The Company's products are ring-shaped small molecules, called "texaphyrins,"

which are patented agents derived from Pharmacyclics' versatile technology platform for designing and synthesizing energy-potentiating drugs. These texaphyrins localize in cancer cells and atherosclerotic plaque, where they can be activated by forms of energy, including X-ray, chemical and light, to selectively eliminate diseased tissue. The Company's lead texaphyrin-based product candidates are Gd-Tex, a gadolinium texaphyrin molecule being developed for use as a radiation sensitizer (initially in the treatment of brain metastases) and chemosensitizer; LUTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in photodynamic therapy of cancer; ANTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in the photoangioplasty of atherosclerosis; and OPTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in photodynamic therapy of age related macular degeneration (ARMD).

Location

995 East Arques Avenue
Sunnyvale
CA
94086-4521
United States of America

Contact

Phone: 408 774 0330
Fax: 408 774 0340
Email: info@pcyc.com


News Articles [11 Associated News Articles listed on BioPortfolio]

Corvus Aims To Master Adenosine Mechanisms For PD-1/L1 Failures

Emerging Company Profile: CEO Richard Miller, who co-founded Idec and Pharmacyclics, explains Corvus's approach of building a pipeline around an...    

Pharmacyclics® Triggers Significant Milestone Payment For Mantle Cell Lymphoma Clinical Trial

SUNNYVALE, Calif., Aug. 20, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the clinical trial, SPARK (MCL2001), of ibrutinib in patients with relapsed or refractory ...

Janssen/AbbVie drug approved in graft-versus-host disease

Janssen/AbbVie’s Imbruvica has gained its first use outside of blood cancer, after the FDA approved it for chronic graft-versus-host disease (cGVHD). The decision further vindicates AbbVie’s $21 ...

Adicet Bio Appoints Jesse McGreivy Chief Medical Officer

Jesse McGreivy is joining Adicet Bio to become the Menlo Park, CA, company’s chief medical officer. McGreivy most recently served as chief medical officer at Redwood City, CA, cancer drug developer ...

FDA approves Imbruvica as first therapy for chronic graft-versus-host disease

The FDA approved ibrutinib for the treatment of adults with chronic graft-versus-host disease who failed prior systemic therapy.Ibrutinib (Imbruvica; Pharmacyclics, Janssen) — a Bruton’s tyrosine ...

Pharmacyclics® Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial

SUNNYVALE, Calif., Oct. 15, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the international, randomized Phase III clinical trial (CLL3001) of ibrutinib (PCI-32765) in co...

Pharmacyclics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27072017] Prices from USD $250

SummaryPharmacyclics Inc Pharmacyclics, a whollyowned subsidiary of AbbVie discovers, develops and commercializes novel therapies for the treatment of cancer and immunemediated diseases. The company's...

Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration

SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the U.S. Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

AERODYNAMIC PROPERTIES AND IN SILICO DEPOSITION OF MELOXICAM POTASSIUM INCORPORATED IN A CARRIER-FREE DPI PULMONARY SYSTEM.

Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung dep...

Clinical Trials [0 Results]

None

Companies [38 Associated Companies listed on BioPortfolio]

Pharmacyclics, Inc.

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune-mediated diseases and cancer. Our mi...

Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC

Pharmacyclics Incorporated

Pharmacyclics, Inc. is a pharmaceutical company developing energy-potentiating drugs to improve radiation therapy andchemotherapy of cancer, and to enable or improve the photodynamic therapy of certai...

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

Pharmapraxis

Founded in 2008 by the Axis Biotec Brasil™ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....

More Information about "Pharmacyclics Incorporated" on BioPortfolio

We have published hundreds of Pharmacyclics Incorporated news stories on BioPortfolio along with dozens of Pharmacyclics Incorporated Clinical Trials and PubMed Articles about Pharmacyclics Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmacyclics Incorporated Companies in our database. You can also find out about relevant Pharmacyclics Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Corporate Database Quicklinks



Searches Linking to this Company Record